UBS Group AG Purchases 348,753 Shares of Heartflow, Inc. $HTFL

UBS Group AG lifted its stake in shares of Heartflow, Inc. (NASDAQ:HTFL) by 228.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 501,165 shares of the company’s stock after acquiring an additional 348,753 shares during the period. UBS Group AG’s holdings in Heartflow were worth $14,609,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Legal & General Group Plc bought a new stake in shares of Heartflow during the third quarter worth $59,000. Y Intercept Hong Kong Ltd bought a new stake in shares of Heartflow during the third quarter worth $234,000. Legato Capital Management LLC bought a new stake in shares of Heartflow during the third quarter worth $243,000. Sandia Investment Management LP bought a new stake in shares of Heartflow during the third quarter worth $252,000. Finally, Hudson Bay Capital Management LP acquired a new position in Heartflow during the third quarter worth $288,000.

Analysts Set New Price Targets

Several research analysts recently commented on HTFL shares. Wells Fargo & Company reduced their target price on shares of Heartflow from $38.00 to $35.00 and set an “overweight” rating for the company in a report on Thursday, March 19th. Canaccord Genuity Group increased their target price on shares of Heartflow from $40.00 to $43.00 and gave the stock a “buy” rating in a report on Thursday, March 19th. William Blair started coverage on shares of Heartflow in a report on Monday, May 4th. They set an “outperform” rating for the company. Finally, JPMorgan Chase & Co. reduced their target price on shares of Heartflow from $40.00 to $35.00 and set an “overweight” rating for the company in a report on Thursday, March 19th. Six analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Heartflow presently has an average rating of “Moderate Buy” and an average target price of $37.67.

Heartflow Trading Up 6.1%

Shares of HTFL opened at $31.20 on Thursday. Heartflow, Inc. has a 12 month low of $20.13 and a 12 month high of $41.22. The firm has a fifty day simple moving average of $27.02 and a 200 day simple moving average of $28.91. The stock has a market capitalization of $2.69 billion and a price-to-earnings ratio of -15.68.

Insider Activity

In other Heartflow news, major shareholder Bain Capital Life Sciences Inv sold 948,757 shares of the stock in a transaction on Thursday, April 30th. The shares were sold at an average price of $29.23, for a total value of $27,732,167.11. Following the completion of the sale, the insider owned 8,448,158 shares in the company, valued at $246,939,658.34. This trade represents a 10.10% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Julie A. Cullivan sold 9,122 shares of the stock in a transaction on Thursday, March 5th. The shares were sold at an average price of $25.00, for a total transaction of $228,050.00. Following the completion of the sale, the director owned 27,291 shares of the company’s stock, valued at approximately $682,275. This represents a 25.05% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 2,205,874 shares of company stock worth $64,166,729. 7.70% of the stock is owned by insiders.

About Heartflow

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.